Active	Status	Sponsor type	Region	Phase	Filter
5 Active 1 Inactive 6 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

5 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Birkenfeld, Andreas
NCT06054035: SGLT2 Inhibition in Addition to Lifestyle Intervention and Risk for Complications in Subtypes of Patients With Prediabetes	Recruiting	4	182	Europe	Dapagliflozin (Forxiga®), Placebo matching Dapaglifolzin, Lifestyle Intervention	University Hospital Tuebingen, German Federal Ministry of Education and Research, German Center for Diabetes Research, AstraZeneca	Type2diabetes, PreDiabetes, Renal Failure	03/26	12/26
SURMOUNT-MMO, NCT05556512: A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity	Active, not recruiting	3	15374	Europe, Canada, Japan, US, RoW	Tirzepatide, LY3298176, Placebo	Eli Lilly and Company	Obesity, Overweight	10/27	10/27
PERI-DYS, NCT03110432: Prospective German Very High Cardiovascular Risk Patients Dyslipidemia Treatment Indication Registry	Active, not recruiting	N/A	1713	Europe	PCSK9 Inhibitor [EPC], Repatha, Praluent, Standard lipid lowering therapy, Statins, ezetimibe, nicotinic acid, fibrates, cholestagel, omega-3 fatty acids	GWT-TUD GmbH	Dyslipoproteinemias	03/24	06/24
NCT06487832: Effect of GLP1 Receptor Agonist on Brain Insulin Responsiveness	Recruiting	N/A	60	Europe	Subcutaneous GLP1-RA, Subcutaneous placebo	University Hospital Tuebingen	Normal Weight, Overweight and Obesity, Insulin Sensitivity, Insulin Resistance	07/27	12/27
acEx, NCT06039787: Exercise Training on Brain Insulin Responsiveness	Recruiting	N/A	40	Europe	single bout of moderate intensity continuous training (MICT), single bout of High Intensity Interval Training (HIIT), waiting control	University Hospital Tuebingen	Insulin Resistance, Obesity	12/26	12/26